Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

TLX Delivers Clinical Progress

It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet period, especially following recent market nerves around the FDA slowdown and a few ASX announcement missteps. Today, the company reported an important milestone in its PROSTACT Global Phase 3 trial, confirming that the first patient has now been dosed in the randomised treatment expansion.

Telix is currently advancing TLX591, its next-generation prostate cancer therapy. TLX591 is a PSMA-targeted radio-antibody, designed to deliver highly targeted radiation directly to prostate cancer cells.

PSMA, or prostate-specific membrane antigen, is a protein that is overexpressed on prostate cancer cells. TLX591 binds to this PSMA marker and delivers a beta-emitting isotope, which then kills the cancer cell through precise radiation while minimising damage to surrounding healthy tissue.

This is the type of update investors have been waiting for, a tangible sign that Telix is continuing to execute clinically, even as sentiment has been shaky. The successful dosing in the Phase 3 expansion is an encouraging step forward in one of Telix’s most important pipeline programs.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Next Stop, Phase 3

Telix’s prostate cancer therapy TLX591 is being advanced through a global Phase 3 program called PROSTACT Global. The drug has already completed Phase 1 and is now moving through Phase 2, where it’s being compared directly against current standard-of-care treatments.

The big milestone ahead is the Phase 3 execution, which will require around 490 patient enrolments. Strong data from this stage will be critical. Once completed, Telix will submit the results to the FDA for review, paving the way for potential US commercial authorisation.

If everything progresses smoothly, we could see meaningful Phase 2 updates and momentum into full Phase 3 within the next 12 months, with final outcomes expected around 2027–2028.

TLX Delivers 53% Revenue Growth, Reaffirms A$800M+ FY Guidance

In Telix’s latest financials, the company delivered a strong result, with revenue up 53 percent to A$206 million. Management also reaffirmed full-year guidance of A$800–820 million, signalling confidence in ongoing commercial momentum.

Illuccix, Telix’s leading imaging asset, continues to perform well and is now approved in 19 European markets. It remains the company’s primary revenue driver, generating operating margins of around 33 percent, which shows Telix is building a high-value, cash-generating product base.

On the balance sheet, TLX currently holds A$384 million in debt, compared to A$207 million in cash. While this means debt exceeds cash, Telix is approaching a profitability inflection point, so we don’t see this as an immediate concern, though it’s something investors should continue to monitor. Much of the cash outflow in the period was tied to acquisitions and contingent payments, with a A$229 million charge noted in the FY25 interim report, reflecting Telix’s strategy of expanding its pipeline and commercial footprint.

Overall, the latest financials show a company that is scaling quickly, supported by a commercially proven asset and a maturing pipeline, while still requiring prudent balance-sheet oversight as it invests for growth.

The Investors Takeaway for TLX

For investors, there are several clear positives in the Telix story right now, including strong global demand for Illuccix, growing cash generation, and meaningful pipeline optionality as TLX591 and other assets progress through development. If Telix can successfully bring a second flagship product to market, it would materially expand the company’s revenue base.

Of course, this comes with clinical and regulatory risks. Telix still needs to demonstrate efficacy in large, randomised trials, and the FDA review process can take longer than expected. These factors will continue to drive volatility until the company reaches more advanced clinical milestones.

Consensus research from 12 analysts currently places an average price target of around A$27, with a bull case closer to A$34. Given Telix is down roughly 40 percent year-to-date, we think the base case upside is reasonable, particularly if sentiment stabilises and clinical progress continues as planned.

On valuation, Telix is trading at around 5.3 times sales based on the June 30 results, with FY26 revenue growth expected to be around 16%. That multiple is not cheap, but it does reflect the company’s rapid growth rate and its position as one of the leading radiopharmaceutical companies globally.

For growth-focused investors, Telix is a company worth researching more deeply. It offers substantial upside potential, but that opportunity is tied to successful clinical execution and timely regulatory engagement, which remain the key risks to monitor.